BioTech Stock Report today announced the release of its July 2003 issue
Beaverton, OR– June 27, 2003. The July report provides an outlook on Crohn’s disease therapeutics. In the U.S., CD affects approximately one million individuals, with men and women equally affected and appear to run in some families. About 20% of people with CD have a blood relative with some form of IBD, most often a brother or sister and sometimes a parent or child. Although IBD are uncommon and rarely fatal, the condition typically occurs during the period of an economically productive adult life, which imposes a significant financial burden on the patient and the patient's family. Patients usually require extensive therapeutic intervention as a result of the chronic, relapsing nature of the disease, which makes CD a long-term healthcare problem that carries significant economic consequences.  The July 2003 issue presents scientific background necessary to understand the market for asthmatic therapies, and introduces the investor to important considerations when investing in biotechnology companies addressing Crohn’s disease. More importantly, you will learn about the progress of new medicines.  Among the companies highlighted in this issue are: Millennium, Celgene, and Protein Design Labs, Biogen, to name a few.  To learn more about BioTech Stock Report, visit http://www.biostockreport.com.  BioTech Stock Report is published monthly. It has set the standard for independent analysis of the biotechnology sector since 1997, as the leader of independent research regarding biotechnology companies specializing in the development of innovative therapies for diseases. Hardcopy or electronic delivery of the BioTech Stock Report is available.  Subscription Rates: 6 months trial subscription for $150, 1 year subscription for $299 or 2 years subscription for $495.  Outside the U.S./Canada add $36 per year for hardcopy via airmail. For more information contact:  Wong’s BioTech Stock Report, P.O. Box 7274, Beaverton, OR 97007; phone: 503-649-1355; fax: 503-649-4490; Email: info@biostockreport.com  Web Site:  www.biostockreport.com   The contents of this publication are based on sources that are believed reliable, but accuracy cannot be guaranteed. This is not an offer to buy or sell securities. BioTech Stock Report is not a registered securities dealer. The information and opinions are for informational purposes only, and are not intended as investment advice. The companies discussed may carry significant investment risk. Readers should review information thoroughly with a registered investment advisor or stockbroker. The publisher and its directors or employees may have positions in and make purchases or sales of securities discussed in this publication.
To subscribe to the Biotech Stock Report - click here! DISCLAIMER The above information transmitted via BioPortfolio has been provided by the original publishers Nadine Wong of Wong & Wong Inc the publishers of the Biotech Stock Report and http://www.biostockreport.com  ("BSN") a financial information, news, and software service focusing on event-driven biotechnology and pharmaceutical research. The Service is provided by Nadine Wong of Wong & Wong Inc ("NWWW").  It is not guaranteed as to completeness or accuracy by BioPortfolio, the BSN publishers, or any person. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company. Opinions expressed are subject to change without notice. The Information and views provided by BSN are prepared by BSN employees and in no way reflect the views or efforts of BioPortfolio Limited., any of BioPortfolio's employees or officers. BioPortfolio, and BioPortfolio's employees and officers, as well as BSN’s employees and officers, in no way accept responsibility for any of the BSN content published on www.bioportfolio.com/.  While all reasonable care has been taken to ensure that the Information contained herein is presented in good faith, and is not untrue or misleading at the time of publication, BioPortfolio, and BSN make no representation as to its accuracy or completeness and it should not be relied upon as such. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. From time to time, BioPortfolio and any officers or employees of BioPortfolio, as well as BSN, and any officers or employees of BSN, may, to the extent permitted by law, have a position or otherwise be interested in any transactions, in any investments (including derivatives) directly or indirectly the subject of this report. Also BioPortfolio and BSN may, from time to time solicit business from any company mentioned in this report. This report is provided solely for the information of viewers of BioPortfolio and/or viewers and subscribers of BSN and BioPortfolio information services, who are expected to make their own investment decisions without reliance on this report. Neither BioPortfolio nor any officer or employee of BioPortfolio, nor BSN, or any officer or employee of BSN, accepts any liability whatsoever for any direct, indirect, special or consequential damages or loss arising from any use of this report or their contents. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, trademark or copyright of BioPortfolio, BSN or any third party.  The value of the investment(s) to which this report relates and their income yield(s) may go up or down. The investment(s) referred to in this report may not be suitable for private investors: if you are in any doubt you should seek advice from your investment advisor. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments. Statements as to past performance of any investment are not a guide to future performance. The levels and bases of taxation can change, and if you are in doubt you should seek independent professional advice. In some cases it may be difficult for you to sell or realize your investment or to obtain reliable information about its value or the extent of the risks to which you are exposed.  THIS INFORMATION IS PROVIDED "AS IS" AND NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED OF ACCURACY, MERCHANTIBILITY FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER NATURE ARE MADE WITH RESPECT TO THIS INFORMATION OR TO ANY EXPRESSED VIEWS PRESENTED IN THIS INFORMATION.